Research and Markets: Musculoskeletal Disorders Therapeutics Market to 2017 - Moderate Growth as Generic Share Continues to Rise

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f1260a/musculoskeletal_di) has announced the addition of the "Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014" report to their offering.

“Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”

GBI Research, the leading business intelligence provider, has released its latest report, Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in the global musculoskeletal disorders as well as in each indication market. It also provides the treatment flow algorithm for each of the five indications.

The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan. The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the musculoskeletal disorders therapeutics market in recent years.

In 2010, the global musculoskeletal disorders market was approximately $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017. The major reason behind the growth rate is the approval of Prolia (denosumab) during 2010. Although the market for management is highly competitive, blockbuster sales of Cymbalta (duloxetine HCl) coupled with improved diagnosis is expected to drive the market in the future.

Companies Mentioned:

• Abbott Laboratories
• Johnson & Johnson
• Amgen Inc.
• Pfizer Inc
• Eli Lilly and Company

For more information visit http://www.researchandmarkets.com/research/f1260a/musculoskeletal_di